4 recruiting, 2 active not recruiting, 1 completed. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Active not recruiting 2, Completed 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow High Grade B-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of High Grade B-Cell Lymphoma, Not Otherwise Specified trials Research Report on High Grade B-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies IDP-121 - Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 37 | 2023-06-05 | 2025-05-01 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 1 | Completed | Northwestern University | 12 | 2019-03-13 | 2025-06-18 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 276 | 2011-08-26 | 2026-07-15 |
Lymphoma, Large B-Cell, Diffuse (6) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Hairy Cell (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1) · Multiple Myeloma (1) · Plasmablastic Lymphoma (1) · Pyloric Stenosis, Hypertrophic (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell (5) · Hematologic Diseases (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · DNA Virus Infections (2)
Cyclophosphamide (5) · Prednisone (4) · Rituximab (4) · Doxorubicin (3) · Vincristine (3) · deltacortene (3) · CT-P10 (2) · Etoposide (2) · glofitamab (2) · prednylidene (2) · Bendamustine Hydrochloride (1) · Biopsy (1) · Cytarabine (1) · Dexamethasone (1) · Inotuzumab Ozogamicin (1)
City of Hope Medical Center (1) · IDP Discovery Pharma S.L. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · University of Washington (1) · Verismo Therapeutics (1)
United States (6) · Spain (1)
Elias Jabbour, MD (1) · Enrique Ocio San Miguel, MD, PhD (1) · Laura A Johnson, PhD (1) · Reem Karmali (1) · Ryan Lynch (1) · Stefan K Barta (1) · Tanya Siddiqi (1)
PMID 28859185, PMID 29352703, PMID 34492703, PMID 35622074, PMID 36521030, PMID 37131217, PMID 37187201, PMID 38551807, PMID 40802906, PMID 41671463
P30CA033572 (1), P30CA060553 (1), UM1CA121947 (1)